Search

Your search keyword '"Lichtenstein, Gary R"' showing total 2,009 results

Search Constraints

Start Over You searched for: Author "Lichtenstein, Gary R" Remove constraint Author: "Lichtenstein, Gary R"
2,009 results on '"Lichtenstein, Gary R"'

Search Results

52. Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine: A Meta-analysis

54. Colaboradores

56. Biologic Therapies

60. Efficacy of Risankizumab Maintenance Therapy by Clinical Remission and Endoscopic Improvement Status in Patients With Moderately to Severely Active Ulcerative Colitis: Post Hoc Analysis of the COMMAND Phase 3 Study.

61. Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With Up to 3 Years of Treatment.

62. The Efficacy of Maintenance Treatment With Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase Inhibitor History.

63. Safety of Long-Term Ozanimod Treatment Up to 5 Years in Patients With Moderately to Severely Active Ulcerative Colitis: An Interim Analysis of the True North Open-Label Extension.

64. Histologic and Combined Histologic and Endoscopic Outcomes After Guselkumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Week 44 Results From the Phase 3 QUASAR Maintenance Study.

65. Corticosteroid-Sparing Effects of Treatment With Guselkumab in Patients With Moderate to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results Through Week 44.

66. Efficacy and Safety of Guselkumab Maintenance Therapy Among Guselkumab Induction Week 24 Clinical Responders: Results From the Phase 3 QUASAR Maintenance Study.

76. Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program

77. Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary

82. PParγ Ligands and Intestinal Inflammation

92. Scintigraphy

97. Tu1480: EFFICACY AND SAFETY OF TOFACITINIB IN ULCERATIVE COLITIS PATIENTS WITH EXTRAINTESTINAL MANIFESTATIONS IN OCTAVE OPEN

98. Tu1446: THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 2B QUASAR STUDY RESULTS THROUGH WEEK 12

99. 15: LONG-TERM CARDIAC SAFETY OF OZANIMOD IN PHASE 3 CLINICAL PROGRAM OF ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS

Catalog

Books, media, physical & digital resources